Latest Capecitabine Stories
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from its ongoing Phase I/II clinical trial of ispinesib were presented in a poster at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium held on September 5-7, 2008 in Washington, DC.
By LAURA NAYLOR Cancer sufferer Liam Hyland is travelling to Turkey every three weeks to buy the medication he hopes will keep him alive. The 63-year-old, of Penkhull, is spending pounds400 each time on oral chemotherapy tablets for his liver cancer.
The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in combination with capecitabine, an oral chemotherapy agent commonly used in the treatment of breast cancer.
By Claire Harrison Dr Seamus McAleer has been involved in trials of a new drug called Lapatinib at Belfast City Hospital which has offered women suffering a type of advanced breast cancer hope by slowing the disease.
NUTLEY, N.J., April 18 /PRNewswire/ -- A novel biweekly dosing schedule of Xeloda(R) (capecitabine) enabled safe delivery of higher daily doses in the treatment of advanced breast cancer, according to an investigational study published in the April 10, 2008 issue of the Journal of Clinical Oncology.
Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients.
Drugmaker Roche Holding AG said on Thursday its Xeloda oral chemotherapy was as effective as standard drugs in treating advanced stomach cancer, supporting analysts' views of higher sales potential.
- A political dynamiter.